UNASSIGNED: @entity4149 kinase inhibitors of the @entity470 ( @entity470 ) are becoming the standard treatment option for @entity1 with advanced @entity1149 ( @entity1149 ) harboring an @entity470 mutation, but the economic impact of this practice is unclear, especially in a health resource-limited setting. A decision-analytic model was developed to simulate 21-day @entity1 transitions in a 10-year time horizon. The health and economic outcomes of four first-line strategies (pemetrexed plus @entity900 [PC] alone, PC followed by maintenance with pemetrexed, or initial treatment with @entity4562 or @entity41059 ) among @entity1 harboring @entity470 mutations were estimated and assessed via indirect comparisons. Costs in the Chinese setting were estimated. The primary outcome was the incremental cost-effectiveness ratio (ICER). Sensitivity analyses were performed. The @entity41059 strategy resulted in greater health benefits than the other three strategies in @entity1149 @entity1 harboring @entity470 mutations. Relative to PC alone, PC followed by pemetrexed maintenance, @entity4562 and @entity41059 resulted in ICERs of  104,657,  28,485 and  19,809 per quality-adjusted life-year gained, respectively. The cost of pemetrexed, the @entity470 mutation prevalence and the utility of progression-free survival were factors that had a considerable impact on the model outcomes. When the @entity41059 @entity1 Assistance Program was available, the economic outcome of @entity41059 was more favorable. These results indicate that gene-guided therapy with @entity41059 might be a more cost-effective treatment option than traditional chemotherapy.

Cost-effectiveness of @entity4562 , XXXX , and pemetrexed-based chemotherapy as first-line treatments for advanced @entity1149 in China.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient'] @entity4562 :: ('MESH:C419708', 'Chemical') :: ['gefitinib'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity41059 :: ('MESH:C531470', 'Chemical') :: ['icotinib'] @entity4149 :: ('D014443', 'Chemical') :: ['Tyrosine']
@entity41059 :: (MESH:C531470,Chemical) :: ['icotinib']
